Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts

Cancer Research

Volumn 62, Issue 3, 2002, Pages 764-772

  Geoerger, Birgit ^a,b   Grill, Jacques ^a,b,c   Opolon, Paule ^b   Morizet, Jackie ^b   Aubert, Geneviève ^b   Terrier Lacombe, Marie José ^b   Bressac de Paillerets, Brigitte ^b   Barrois, Michel ^b   Feunteun, Jean ^b   Kirn, David H ^d   Vassal, Gilles ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ONYX 015; PROTEIN P53;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CYTOLYSIS; FEMALE; GENE DELETION; GENE THERAPY; GLIOMA; GROWTH INHIBITION; GROWTH RATE; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; TREATMENT FAILURE; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION; VIRUS REPLICATION; XENOGRAFT;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMALS; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MIDDLE AGED; RECEPTORS, VIRUS; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036468548     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Glioblastoma multiforme: The terminator
2. p53 mutations in human malignant gliomas: Comparison of loss of heterozygosity with mutation frequency
3. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas
4. Analysis of the p53 gene and its expression in human glioblastoma cells
5. Mechanisms of cross-resistance between radiation and antineoplastic drugs
6. Antineoplastic drug resistance in brain tumors
7. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
8. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
9. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
10. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
11. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
12. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
13. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
14. p53-dependent cell death/apoptosis is required for a productive adenoviros infection
15. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status
16. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
17. Oncogenic potential of the adenovirus FAorf6 protein
18. The adenovirus FAorf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function
19. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells
20. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015)
21. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53
22. Human tumor xenografts as model for drug testing
23. Tumorigenicity of cerebellar primitive neuro-ectodermal tumors in athymic mice correlates with poor prognosis in children
24. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
25. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity
26. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts
27. Screening patients for heterozygous p53 mutations using a functional assay in yeast
28. A simple p53 functional assay for screening cell lines, blood, and tumors
29. A functional screen for germ line p53 mutations based on transcriptional activation
30. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
31. TaqMan PCR-based gene dosage assay for predictive testing in individuals from a cancer family with INK4 locus haploinsufficiency
32. Detection of single-nucleotide polymorphisms with the WAVE DNA fragment analysis system
33. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
34. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids
35. Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer
36. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
37. The INK4a/ARF tumor suppressor: One gene-two products-two pathways
38. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
39. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein
40. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication
41. Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?
42. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
43. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53
44. The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21(BAX) expression
45. Early events of virus-cell interaction in an adenovirus system
46. Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy
47. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer
48. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures
49. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection